<DOC>
	<DOC>NCT02190786</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy, safety and pharmacokinetics of multiple oral administration of KUX-1151 in patients with hyperuricemia including gout.</brief_summary>
	<brief_title>Phase II Exploratory Clinical Study of KUX-1151</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<criteria>Japanese HU patients (Outpatient) Patients who meet the following criteria concerning serum uric acid levels at the screening [1) Gout: &gt; 7.0 mg/dL, 2) HU with complications: ≥ 8.0 mg/dL, 3) HU without complications: ≥ 9.0 mg/dL] Patients who have any symptom of gouty arthritis within 2 weeks of investigational product administration</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Hyperuricemia</keyword>
</DOC>